Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced a study revealing that more patients completed hereditary cancer testing when they used an online ...
Myriad Genetics announces hereditary cancer risk assessment study published
Myriad Genetics (MYGN) announced a study revealing that more patients completed hereditary cancer testing when they used an online screening ...
EurekAlert!1d
Gene classifier tests for prostate cancer may influence treatment decisions despite lack of evidence for long-term outcomes
A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...
News Medical1d
Exploring the use of genomic classifier tests in prostate cancer risk stratification
A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...
bovnews3d
Myriad Genetics Inc (MYGN) Posted -14.08% Profit Margin Last Year—Can It Hold Up?
Myriad Genetics Inc (MYGN) stock saw a decline, ending the day at $12.39 which represents a decrease of $-0.13 or -1.04% from the prior close of $12.52. The stock opened at $12.56 and touched a low of ...
360dx5d
At JP Morgan, Myriad Genetics Says Q4 Test Volumes Disappointing, Firm Preps New Launches in 2025
SAN FRANCISCO — At the JP Morgan Healthcare Conference here on Wednesday, Myriad Genetics CEO Paul Diaz provided preliminary Q4 and full-year 2024 financial results, as well as full-year 2025 guidance ...
Myriad Genetics: Navigating Through A Setback
Myriad Genetics faces a tough year ahead with new policy changes. Learn why MYGN stock has cratered and if it's poised for ...
Myriad Genetics (NASDAQ:MYGN) Stock Rating Upgraded by StockNews.com
Myriad Genetics (NASDAQ:MYGN – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating to a ...
Hosted on MSN11d
MYGN Stock Gains Following Collaboration With Hannah Storm
Myriad Genetics, Inc. MYGN recently announced an agreement with Hannah Storm, a nationally renowned sports broadcaster who ...
New tool puts reproductive risk for BRCA carriers into perspective
"I just wish someone had told me this was a possibility." Kara Maxwell distinctly remembers the moment she heard those words ...
TMCnet13d
UPDATE - Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, President and CEO, and Sam ...
Yahoo Finance15d
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
Myriad Genetics, Inc. HOUSTON and SALT LAKE CITY, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year ...